Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorRodriguez-Moreno, J. F.
dc.contributor.authorde Velasco, G.
dc.contributor.authorAlvarez-Fernandez, C.
dc.contributor.authorCollado, R.
dc.contributor.authorFernandez-Rodriguez, R.
dc.contributor.authorVazquez Estevez, S.
dc.contributor.authorVirizuela Echaburu, J. A.
dc.contributor.authorGajate Borau, P.
dc.contributor.authorFont, A.
dc.contributor.authorLainez, N.
dc.contributor.authorSevillano Fernandez, E.
dc.contributor.authorRuiz, S.
dc.contributor.authorBeltran, L.
dc.contributor.authorRodriguez-Antona, C.
dc.contributor.authorBerraondo, P.
dc.contributor.authorGarcia-Donas, J.
dc.contributor.authoraffiliation[Rodriguez-Moreno, J. F.] Ctr Integral Oncol HM Clara Campal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Sevillano Fernandez, E.] Ctr Integral Oncol HM Clara Campal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Garcia-Donas, J.] Ctr Integral Oncol HM Clara Campal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[de Velasco, G.] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Alvarez-Fernandez, C.] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain
dc.contributor.authoraffiliation[Collado, R.] Complejo Hosp Caceres, Med Oncol, Caceres, Spain
dc.contributor.authoraffiliation[Fernandez-Rodriguez, R.] Inst Oncol IMQ Bilbao, Med Oncol, Bilbao, Bizkaia, Spain
dc.contributor.authoraffiliation[Vazquez Estevez, S.] Hosp Xeral Calde Lugo, Med Oncol, Lugo, Spain
dc.contributor.authoraffiliation[Virizuela Echaburu, J. A.] Hosp Univ Virgen Macarena, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Gajate Borau, P.] Hosp Univ Ramon & Cajal, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Font, A.] Inst Catala Oncol, Oncol, Badalona, Spain
dc.contributor.authoraffiliation[Lainez, N.] Complejo Hosp Navarra, Med Oncol Dept, Pamplona, Spain
dc.contributor.authoraffiliation[Ruiz, S.] Ctr Integral Oncol HM Clara Campal, Lab Innovac Canc, Madrid, Spain
dc.contributor.authoraffiliation[Beltran, L.] Barts Hlth NHS Trust, Pathol, London, England
dc.contributor.authoraffiliation[Rodriguez-Antona, C.] Spanish Natl Canc Res Ctr, Human Canc Genet Programme, Madrid, Spain
dc.contributor.authoraffiliation[Berraondo, P.] Royal Navarre Hosp, Complejo Hosp Navarra, Immunol, Pamplona, Spain
dc.contributor.funderAstraZeneca
dc.date.accessioned2025-01-07T16:06:07Z
dc.date.available2025-01-07T16:06:07Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.833
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420408294/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27617
dc.identifier.wosID573469101049
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS589-S589
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleImpact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía